JNK inhibitors increase osteogenesis in Nf1-deficient cells

Bone

Volumn 49, Issue 6, 2011, Pages 1311-1316

  Sullivan, Kate ^a,b   El Hoss, Jad ^a   Little, David G ^a,b   Schindeler, Aaron ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b University of Sydney   (Australia)

Author keywords

Bone morphogenetic protein; C Jun N terminal kinase inhibitor; Mitogen activated protein kinase; Neurofibromatosis type 1; NF1

Indexed keywords

ALKALINE PHOSPHATASE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BONE MORPHOGENETIC PROTEIN 2; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DEVELOPMENT; BONE MINERALIZATION; CELL MATURATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; OSTEOBLAST; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT RESPONSE;

ANIMALS; ANTHRACENES; BIOLOGICAL MARKERS; BONE MARROW CELLS; BONE MORPHOGENETIC PROTEIN 2; CALCIFICATION, PHYSIOLOGIC; CELL DIFFERENTIATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MYOBLASTS; NEUROFIBROMIN 1; OSTEOGENESIS; PROTEIN KINASE INHIBITORS; RAS PROTEINS; RECOMBINANT PROTEINS; SKULL; STROMAL CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 81355160356     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.09.043     Document Type: Article

References (30)

1. Schindeler A., Morse A., Harry L., Godfrey C., Mikulec K., McDonald M., et al. Models of tibial fracture healing in normal and Nf1-deficient mice. J Orthop Res 2008, 26:1053-1060.
2. Yang F.C., Chen S., Robling A.G., Yu X., Nebesio T.D., Yan J., et al. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J Clin Invest 2006, 116:2880-2891.
3. Schindeler A., Ramachandran M., Godfrey C., Morse A., McDonald M., Mikulec K., et al. Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type and Nf1 haploinsufficient mice. J Orthop Res 2008, 26:65-74.
4. Klose A., Ahmadian M.R., Schuelke M., Scheffzek K., Hoffmeyer S., Gewies A., et al. Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1. Hum Mol Genet 1998, 7:1261-1268.
5. Kuorilehto T., Ekholm E., Nissinen M., Hietaniemi K., Hiltunen A., Paavolainen P., et al. NF1 gene expression in mouse fracture healing and in experimental rat pseudarthrosis. J Histochem Cytochem 2006, 54:363-370.
6. Nakamura H., Hirata A., Tsuji T., Yamamoto T. Role of osteoclast extracellular signal-regulated kinase (ERK) in cell survival and maintenance of cell polarity. J Bone Miner Res 2003, 18:1198-1205.
7. Schindeler A., Little D.G. Ras-MAPK signaling in osteogenic differentiation: friend or foe?. J Bone Miner Res 2006, 21:1331-1338.
8. Daginakatte G.C., Gianino S.M., Zhao N.W., Parsadanian A.S., Gutmann D.H. Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation. Cancer Res 2008, 68:10358-10366.
9. Brannan C.I., Perkins A.S., Vogel K.S., Ratner N., Nordlund M.L., Reid S.W., et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 1994, 8:1019-1029.
10. Zhu Y., Romero M.I., Ghosh P., Ye Z., Charnay P., Rushing E.J., et al. Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev 2001, 15:859-876.
11. Katagiri T., Yamaguchi A., Komaki M., Abe E., Takahashi N., Ikeda T., et al. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol 1994, 127:1755-1766.
12. Schindeler A., Morse A., Peacock L., Mikulec K., Yu N.Y., Liu R., et al. Rapid cell culture and pre-clinical screening of a transforming growth factor-beta (TGF-beta) inhibitor for orthopaedics. BMC Musculoskelet Disord 2010, 11:105.
13. Schindeler A., Little D.G. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro. Biochem Biophys Res Commun 2005, 338:710-716.
14. Bosch P., Fouletier-Dilling C., Olmsted-Davis E.A., Davis A.R., Stice S.L. Efficient adenoviral-mediated gene delivery into porcine mesenchymal stem cells. Mol Reprod Dev 2006, 73:1393-1403.
15. Cheung W.M., Ng W.W., Kung A.W. Dimethyl sulfoxide as an inducer of differentiation in preosteoblast MC3T3-E1 cells. FEBS Lett 2006, 580:121-126.
16. Matsuguchi T., Chiba N., Bandow K., Kakimoto K., Masuda A., Ohnishi T. JNK activity is essential for Atf4 expression and late-stage osteoblast differentiation. J Bone Miner Res 2009, 24:398-410.
17. Lai C.F., Cheng S.L. Signal transductions induced by bone morphogenetic protein-2 and transforming growth factor-beta in normal human osteoblastic cells. J Biol Chem 2002, 277:15514-15522.
18. Schindeler A., Little D.G. Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1). Bone 2008, 42:616-622.
19. Yu X., Chen S., Potter O.L., Murthy S.M., Li J., Pulcini J.M., et al. Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning. Bone 2005, 36:793-802.
20. Elefteriou F., Benson M.D., Sowa H., Starbuck M., Liu X., Ron D., et al. ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab 2006, 4:441-451.
21. Lau N., Feldkamp M.M., Roncari L., Loehr A.H., Shannon P., Gutmann D.H., et al. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. J Neuropathol Exp Neurol 2000, 59:759-767.
22. Bollag G., Clapp D.W., Shih S., Adler F., Zhang Y.Y., Thompson P., et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 1996, 12:144-148.
23. Sherman L.S., Atit R., Rosenbaum T., Cox A.D., Ratner N. Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts. J Biol Chem 2000, 275:30740-30745.
24. Largaespada D.A., Brannan C.I., Jenkins N.A., Copeland N.G. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet 1996, 12:137-143.
25. Kolanczyk M., Kossler N., Kuhnisch J., Lavitas L., Stricker S., Wilkening U., et al. Multiple roles for neurofibromin in skeletal development and growth. Hum Mol Genet 2007, 16:874-886.
26. Yan J., Chen S., Zhang Y., Li X., Li Y., Wu X., et al. Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1. Hum Mol Genet 2008, 17:936-948.
27. Watanabe-Takano H., Takano K., Keduka E., Endo T. M-Ras is activated by bone morphogenetic protein-2 and participates in osteoblastic determination, differentiation, and transdifferentiation. Exp Cell Res 2009, 316:477-490.
28. Liu H., Liu Y., Viggeswarapu M., Zheng Z., Titus L., Boden S.D. Activation of c-Jun NH(2)-terminal kinase 1 increases cellular responsiveness to BMP-2 and decreases binding of inhibitory Smad6 to the type 1 BMP receptor. J Bone Miner Res 2011, 26:1122-1132.
29. Chung C.Y., Iida-Klein A., Wyatt L.E., Rudkin G.H., Ishida K., Yamaguchi D.T., et al. Serial passage of MC3T3-E1 cells alters osteoblastic function and responsiveness to transforming growth factor-beta1 and bone morphogenetic protein-2. Biochem Biophys Res Commun 1999, 265:246-251.
30. Stevenson D.A., Zhou H., Ashrafi S., Messiaen L.M., Carey J.C., D'Astous J.L., et al. Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum Genet 2006, 79:143-148.